<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260722070303N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-07-24</date_registration>
      <primary_sponsor>University of Tabriz</primary_sponsor>
      <public_title>Combined rTMS for Mild Cognitive Impairment</public_title>
      <acronym></acronym>
      <scientific_title>Combined Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) of the Cerebellum and the Dorsolateral Prefrontal Cortex (DLPFC) on Cognitive Functions in Older Adults with Mild Cognitive Impairment (MCI)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/91811</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants who meet the eligibility criteria and provide written informed consent will be randomly allocated to one of four parallel groups, including Sham stimulation, Cerebellar rTMS, DLPFC rTMS, and Combined Cerebellar plus DLPFC rTMS, with an allocation ratio of 1:1:1:1. Block randomization will be performed using a computer-generated random sequence prepared by an independent researcher. Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes. After completion of the baseline assessment, the intervention operator will open the corresponding envelope and administer the assigned intervention. The participants will remain blinded to group allocation, while the intervention operator will be aware of the assigned group, Blinding description: Participants who meet the eligibility criteria and provide written informed consent will be randomly allocated to one of four parallel groups, including Sham stimulation, Cerebellar rTMS, DLPFC rTMS, and Combined Cerebellar plus DLPFC rTMS, with an allocation ratio of 1:1:1:1. Block randomization will be performed using a computer-generated random sequence prepared by an independent researcher. Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes. After completion of the baseline assessment, the intervention operator will open the corresponding envelope and administer the assigned intervention. The participants will remain blinded to group allocation, while the intervention operator will be aware of the assigned group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Mild Cognitive Impairment (MCI).</hc_freetext>
      <i_freetext>Intervention 1: Control group: transcranial magnetic stimulation over both the cerebellum and the left dorsolateral prefrontal cortex for 10 sessions, one session per day. During each session, the coil will first be positioned over the cerebellar target and then over the left dorsolateral prefrontal cortex. The coil will be held at a 90-degree angle relative to the scalp to prevent effective brain stimulation. The duration and sequence of sham stimulation will be similar to those used in the active intervention groups, using the same device and figure-of-eight coil. Intervention 2: Intervention group:followed by active repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex for 10 sessions, one session per day. First, the coil will be positioned over the cerebellar target at a 90-degree angle relative to the scalp, and sham stimulation corresponding to 1,000 pulses will be administered. Active stimulation will then be applied over the left dorsolateral prefrontal cortex at 10 Hertz, 100 percent of the resting motor threshold, and 2,000 pulses per session using a figure-of-eight coil. Intervention 3: Intervention group:Participants in this group will receive active cerebellar repetitive transcranial magnetic stimulation followed by sham stimulation over the left dorsolateral prefrontal cortex for 10 sessions, one session per day. Active cerebellar stimulation will be delivered at 5 Hertz, 90 percent of the resting motor threshold, and 1,000 pulses per session using a figure-of-eight coil. The coil will then be positioned over the left dorsolateral prefrontal cortex at a 90-degree angle relative to the scalp, and sham stimulation corresponding to 2,000 pulses will be administered. Intervention 4: Intervention group:magnetic stimulation over both the cerebellum and the left dorsolateral prefrontal cortex for 10 sessions, one session per day. Cerebellar stimulation will first be delivered at 5 Hertz, 90 percent of the resting motor threshold, and 1,000 pulses per session. Active stimulation will then be applied over the left dorsolateral prefrontal cortex at 10 Hertz, 100 percent of the resting motor threshold, and 2,000 pulses per session. Both stimulations will be delivered using the same device and figure-of-eight coil.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Deidentified individual participant data, the data dictionary, study protocol, statistical analysis plan, and a blank copy of the informed consent form will be available for sharing. The shared dataset may include demographic variables, group allocation, intervention parameters, and cognitive outcome scores measured before and after the intervention. All information that could identify participants will be removed before data sharing.

When:
Data and supporting documents will be available from 12 months after publication of the main study results and will remain available for 5 years.

To whom:
Researchers affiliated with recognized universities, research institutions, or scientific centers may request access after submitting a specific research proposal that is scientifically and ethically acceptable.

Conditions:
The data may be used for scientific analyses related to mild cognitive impairment, transcranial magnetic stimulation, reanalysis of study findings, systematic reviews, and meta-analyses. Access will require approval of the research proposal, a commitment to confidentiality, agreement not to attempt participant identification, and completion of a data use agreement. Commercial use or transfer of the data to third parties without written permission will not be allowed.

Where to obtain:
Requests should be submitted by email to the responsible researcher, Masoud Ghaffarvand Mokari, University of Tabriz, Tabriz, Iran. Applicants should provide their personal and institutional details, the purpose of the request, the proposed analysis plan, and relevant ethics approval documents.

How to obtain:
Requests must be submitted in writing and include the research objective, analysis plan, institutional affiliation of the researchers, and relevant ethics approval. The request will be reviewed by the responsible researcher and the study supervisor. A decision will be communicated within 30 days. Following approval and completion of a data use agreement, the files will be transferred through a secure electronic method.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoud Ghaffarvand-Mokari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University of Tabriz, 29 Bahman Boulevard, Tabriz, East Azerbaijan Province, Iran.</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3334 0081</telephone>
        <email>m.ghaffarvand@gmail.com</email>
        <affiliation>University of Tabriz</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoud Ghaffarvand Mokari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University of Tabriz, 29 Bahman Boulevard, Tabriz, East Azerbaijan Province, Iran.</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3334 1300</telephone>
        <email>m.ghaffarvand@gmail.com</email>
        <affiliation>University of Tabriz</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Adults aged 50 years and older
Diagnosis of Mild Cognitive Impairment according to Petersen
Criteria MoCA score 19-25
Ability to provide informed consent
medication during the previous 4 weeks
Right-handedStable</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Diagnosis of dementia
History of epilepsy or seizure
Metallic implants contraindicated for TMS
Major psychiatric disorders
History of stroke or other severe neurological disease
Current use of medications lowering seizure threshold</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G31.84</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Mild cognitive impairment, so stated</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: transcranial magnetic stimulation over both the cerebellum and the left dorsolateral prefrontal cortex for 10 sessions, one session per day. During each session, the coil will first be positioned over the cerebellar target and then over the left dorsolateral prefrontal cortex. The coil will be held at a 90-degree angle relative to the scalp to prevent effective brain stimulation. The duration and sequence of sham stimulation will be similar to those used in the active intervention groups, using the same device and figure-of-eight coil.</i_keyword>
      <i_keyword>Intervention group:followed by active repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex for 10 sessions, one session per day. First, the coil will be positioned over the cerebellar target at a 90-degree angle relative to the scalp, and sham stimulation corresponding to 1,000 pulses will be administered. Active stimulation will then be applied over the left dorsolateral prefrontal cortex at 10 Hertz, 100 percent of the resting motor threshold, and 2,000 pulses per session using a figure-of-eight coil.</i_keyword>
      <i_keyword>Intervention group:Participants in this group will receive active cerebellar repetitive transcranial magnetic stimulation followed by sham stimulation over the left dorsolateral prefrontal cortex for 10 sessions, one session per day. Active cerebellar stimulation will be delivered at 5 Hertz, 90 percent of the resting motor threshold, and 1,000 pulses per session using a figure-of-eight coil. The coil will then be positioned over the left dorsolateral prefrontal cortex at a 90-degree angle relative to the scalp, and sham stimulation corresponding to 2,000 pulses will be administered.</i_keyword>
      <i_keyword>Intervention group:magnetic stimulation over both the cerebellum and the left dorsolateral prefrontal cortex for 10 sessions, one session per day. Cerebellar stimulation will first be delivered at 5 Hertz, 90 percent of the resting motor threshold, and 1,000 pulses per session. Active stimulation will then be applied over the left dorsolateral prefrontal cortex at 10 Hertz, 100 percent of the resting motor threshold, and 2,000 pulses per session. Both stimulations will be delivered using the same device and figure-of-eight coil.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Episodic memory score. Timepoint: Before the intervention and after completion of 10 intervention sessions. Method of measurement: Rey Auditory Verbal Learning Test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Visuospatial working memory score. Timepoint: Before the intervention and after completion of 10 intervention sessions. Method of measurement: Corsi Block Tapping Test.</sec_outcome>
      <sec_outcome>Executive function score. Timepoint: Before the intervention and after completion of 10 intervention sessions. Method of measurement: Tower of London Test.</sec_outcome>
      <sec_outcome>Global cognitive function score. Timepoint: Before the intervention and after completion of 10 intervention sessions. Method of measurement: Montreal Cognitive Assessment.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Tabriz</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-02-18</approval_date>
        <contact_name>Ethics committee of Tabriz University</contact_name>
        <contact_address>29 Bahman Blvd.,Tabriz, Iran 5166616471 Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
